Released Nov 5, 2026, after the close
10-Q filed Nov 9, 2026, 40 days after period end · 0001628280-26-072290
What the release said
Ginkgo announces material information to the public through a variety of means, including filings with the SEC, public conference calls, its website (https://www.ginkgo.bio), its investor relations website (https://investors.ginkgobioworks.com) and its news site (https://investors.ginkgobioworks.com/news).
Ginkgo reported third quarter 2026 results and announced the sale of an autonomous lab to a top-tier pharma company, Novo, at Novo's new Waltham, Massachusetts R&D site.¶2¶3
Third quarter 2026 revenue was $28 million, compared to $29 million a year earlier, while GAAP net loss from continuing operations was ($41) million versus ($73) million.¶4¶5¶6
Cash, cash equivalents and marketable securities were $285 million as of September 30, 2026, after third quarter 2026 cash burn of $27 million.¶7¶8
A subcontract worth up to $17.5 million under ARPA-H GIVE will put RACs and Catalyst into RNA-medicine manufacturing for the first time.¶9
Ginkgo reaffirmed expected total cash burn of ($150)-($125) million in 2026.¶10
- Third quarter 2026 revenue
- $28 million Compared to $29 million in the comparable prior year period, a decrease of 6%¶4
- Third quarter 2026 GAAP net loss from continuing operations
- ($41) million Compared to ($73) million in the comparable prior year period¶5
- Third quarter 2026 Adjusted EBITDA
- ($22) million Improved from ($53) million in the comparable prior year period¶6
- Cash, cash equivalents and marketable securities
- $285 million As of September 30, 2026¶7
- Full year 2026 expected total cash burn
- ($150)-($125) million Reaffirmed outlook range for 2026¶10
Same quarter
| Metric | Q3 2026 | Q3 2025 | Q3 2024 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $27.71M | $29.38M | $89.05M | $55.43M |
| Net Income | -$40.98M | -$80.76M | -$56.40M | -$302.89M |
| EPS Diluted | — | -$1.45 | -$1.08 | -$6.21 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ginkgo Bioworks Holdings, Inc. · CIK 1830214 · Engraved from SEC EDGAR